secwatch.observer — SEC 8-K summary
======================================

Issuer:     20/20 Biolabs, Inc. (AIDX)
CIK:        0001139685
Form:       8-K
Filed at:   2026-09-10T20:10:32+00:00
Accession:  0001213900-26-098792
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

20/20 Biolabs gets Nasdaq equity non-compliance notice; delisting risk
----------------------------------------------------------------------

- On Sept 3, 2026, Nasdaq notified 20/20 Biolabs of non-compliance with $2.5M stockholders' equity rule; reported equity $1.62M.
- Company has 45 days to submit compliance plan; if accepted, extension up to 180 days possible.
- Also previously notified July 17, 2026 of bid price non-compliance; must regain $1.00 bid by Jan 13, 2027.
- Failure to cure equity by Jan 13, 2027 would also disqualify additional bid-price cure period.
- Company intends to monitor and consider options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/0001213900-26-098792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/ea0305119-8k_2020bio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer